# Long-Acting Treatment in Adolescents (LATA)

> **NCT05154747** · PHASE3 · UNKNOWN · sponsor: **University College, London** · enrollment: 476 (actual)

## Conditions studied

- Hiv
- HIV Infections
- HIV-1-infection
- Paediatric Human Immunodeficiency Virus Infection

## Interventions

- **DRUG:** Cabotegravir, Rilpivirine Drug Combination
- **DRUG:** TLD

## Key facts

- **NCT ID:** NCT05154747
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-22
- **Primary completion:** 2025-03
- **Final completion:** 2026-03
- **Target enrollment:** 476 (ACTUAL)
- **Last updated:** 2024-04-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05154747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05154747, "Long-Acting Treatment in Adolescents (LATA)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05154747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*